Jaguar Health Inc. [NASDAQ: JAGX] loss -4.03% or -0.02 points to close at $0.38 with a heavy trading volume of 1974665 shares. The company report on August 19, 2020 that Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi).
Company shares updates on investigator-initiated trials of crofelemer (Mytesi®), a novel FDA-approved plant-based oral prescription medicine.
Jaguar Health, Inc. (NASDAQ:JAGX) today provided updates regarding ongoing investigator-initiated trials in non-HIV patient populations of crofelemer (Mytesi®), the novel FDA-approved plant-based oral drug developed and marketed by Jaguar’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc.
It opened the trading session at $0.395, the shares rose to $0.415 and dropped to $0.3731, the range by which the price of stock traded the whole day. The daily chart for JAGX points out that the company has recorded -38.59% loss over the past six months. However, it is still -8.57% lower than its most recent low trading price.
If we look at the average trading volume of 5.39M shares, JAGX reached to a volume of 1974665 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Jaguar Health Inc. [JAGX]:
Rodman & Renshaw have made an estimate for Jaguar Health Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 11, 2017.
The Average True Range (ATR) for Jaguar Health Inc. is set at 0.06, with the Price to Sales ratio for JAGX stock in the period of the last 12 months amounting to 2.39. The Price to Book ratio for the last quarter was 12.80, with the Price to Cash per share for the same quarter was set at 0.07.
Trading performance analysis for JAGX stock
Jaguar Health Inc. [JAGX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.24. With this latest performance, JAGX shares dropped by -43.54% in over the last four-week period, additionally sinking by -38.59% over the last 6 months – not to mention a drop of -66.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JAGX stock in for the last two-week period is set at 34.29, with the RSI for the last a single of trading hit 26.81, and the three-weeks RSI is set at 35.99 for Jaguar Health Inc. [JAGX]. The present Moving Average for the last 50 days of trading for this stock 0.5889, while it was recorded at 0.3982 for the last single week of trading, and 0.5861 for the last 200 days.
Jaguar Health Inc. [JAGX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Jaguar Health Inc. [JAGX] shares currently have an operating margin of -420.75 and a Gross Margin at +33.93. Jaguar Health Inc.’s Net Margin is presently recorded at -667.32.
Return on Total Capital for JAGX is now -82.93, given the latest momentum, and Return on Invested Capital for the company is -217.73. Return on Equity for this stock declined to -220.53, with Return on Assets sitting at -99.52. When it comes to the capital structure of this company, Jaguar Health Inc. [JAGX] has a Total Debt to Total Equity ratio set at 36.78. Additionally, JAGX Total Debt to Total Capital is recorded at 26.89, with Total Debt to Total Assets ending up at 20.78. Long-Term Debt to Equity for the company is recorded at 5.02, with the Long-Term Debt to Total Capital now at 1.60.
Reflecting on the efficiency of the workforce at the company, Jaguar Health Inc. [JAGX] managed to generate an average of -$1,328,946 per employee. Receivables Turnover for the company is 4.28 with a Total Asset Turnover recorded at a value of 0.15.Jaguar Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.40 and a Current Ratio set at 0.50.
Jaguar Health Inc. [JAGX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Jaguar Health Inc. posted -15.11/share EPS, while the average EPS was predicted by analysts to be reported at -5.29/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -185.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JAGX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Jaguar Health Inc. go to 40.00%.
An analysis of insider ownership at Jaguar Health Inc. [JAGX]
There are presently around $0 million, or 3.20% of JAGX stock, in the hands of institutional investors. The top three institutional holders of JAGX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 109,183, which is approximately New of the company’s market cap and around 10.37% of the total institutional ownership; VIRTU FINANCIAL LLC, holding 59,529 shares of the stock with an approximate value of $23000.0 in JAGX stocks shares; and TWO SIGMA ADVISERS, LP, currently with $20000.0 in JAGX stock with ownership of nearly New of the company’s market capitalization.
Positions in Jaguar Health Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 9 institutional holders increased their position in Jaguar Health Inc. [NASDAQ:JAGX] by around 262,293 shares. Additionally, 3 investors decreased positions by around 129,399 shares, while 5 investors held positions by with 13,876 shares. The mentioned changes placed institutional holdings at 405,568 shares, according to the latest SEC report filing. JAGX stock had 6 new institutional investments in for a total of 261,027 shares, while 2 institutional investors sold positions of 83,037 shares during the same period.